Nautilus Biotechnology to Report Second Quarter 2026 Financial Results on July 28
Key Insights
Nautilus Biotechnology (NASDAQ: NAUT) will release its Q2 2026 financial results before market open on Tuesday, July 28, 2026.
Management will host a conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook.
The company is pioneering a single-molecule protein analysis platform aimed at transforming proteomics and enabling advances in human health.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a development-stage life sciences company pioneering a single-molecule protein analysis platform, announced it will report its financial results for the second quarter of 2026 before market open on Tuesday, July 28, 2026.
The company's management will host a conference call and simultaneous webcast beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss the quarterly results, provide updates on business developments, and share the company's outlook. Live audio of the webcast will be accessible via the "Investors" section of the company's website at www.nautilus.bio.
Company Background and Mission
Nautilus Biotechnology is headquartered in Seattle, Washington, with its research and development operations based in San Carlos, California. The company is working to create a platform technology designed for quantifying and unlocking the complexity of the proteome. Nautilus describes its mission as transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
As a development-stage company, Nautilus has not yet commercialized its platform but continues to advance its single-molecule protein analysis technology, which aims to provide deeper insights into the proteome than currently available methods.
Investor Access
Investors and interested parties can access the live webcast through the company's investor relations portal. Media inquiries may be directed to press@nautilus.bio, and investor relations questions can be sent to investorrelations@nautilus.bio.